Warner-lambert Company

Cayman Chemical Company Incorporated

Myometrics LLC

Pfizer Corporation

Thesan Pharmaceuticals, Inc.

University of Michigan

Medicis Pharmaceutical Corporation

Graceway Pharmaceuticals, LLC

Fbm Therapeutics, LLC

Stephen Douglas Barrett

Haile Tecle

James Bernard Kramer

Gregory William Endres

Adam Uzieblo

Fred Lawrence Ciske

Andriy Kornilov

Bradlee David Germain

Joseph Michael Colombo

Alexander James Bridges

Kirk M Maxey

Annette Marian Doherty

Alan Robert Saltiel

David Thomas Dudley

Michael David Kaufman

Huifen Chen

Mark Laurence Boys

Thomas Allen Owen

James Paul O'Malley

Mel C Schroeder

Donna Reynolds Cody

Gordon William Rewcastle

Joseph Scott Warmus

Julie Ann Spicer

Jared Bruce John Milbank

Raj Kumar Raheja

Bruce A Lefker

Juan C Jaen

Lain-Yen Hu

Richard John Booth

Karen Elaine Sexton

Victor Fedij

Kirk Lang Olson

Cathlin Marie Biwersi

Donna Michele Iula

Andriy Komilov

Jennifer Ann Van Camp

Pil Heui Lee

David J Lauffer

Walter H Moos

Bradley W Caprathe

Michael R Pavia

Anthony J Thomas

Simon Bailey

Gilles Chambournier

Corinne E Augelli-Szafran

Nancy Sue Barta

Hussein Mahmoud Mahmoud

Michael Huai Gu Chen

Howard Yoshihisa Ando

Raymond C Trievel

Levi Lynn Blazer

Jeffrey Keith Johnson

Steven Edward Rose

Adam A Galan

Kathryn B Sanders

Veerabahu Shanmugasundaram

Cathlin Marie Flamme

Alistair Dixon

Daniel Austin Bochar

Kevin Lee

Robert Pinnock

Lu-Yan Zhang

Gregory Scott Keyes

Ranjinder Singh Sidhu

Margaret Lynn Collins

Ivan Vesely

Michael Chen

James Paul O'malley

Cathlin Biwersi

Jared Bruce Milbank

Bruce Allen Lefker

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions

The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R, R, R, R, and Lare as defined herein. Compounds of formula (IA) have been found useful as EPreceptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders. 

Methods of synthesizing a difluorolactam analog

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

Methods, systems, and compositions for promoting bone growth

Difluorolactam compounds as EPreceptor-selective agonists for use in the treatment of EP-mediated diseases and conditions

The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF&#x3b2;-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

Therapeutic pyrazolyl thienopyridines

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

[object Object]

Disclosed herein are compounds of formula (I) wherein L, L, L, L, R, R, R, R, and s are as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compounds of formula (I) wherein L, L, L, R, R, R, and Rare as defined in the specification. Compounds of formula (I) are EPagonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L, L, L, R, R, R, R, and s are as defined in the specification.

Difluorolactam compositions for EP4-mediated osteo related diseases and conditions

Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin Dmediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).

Growing community of inventors

Hartland, MI, United States of America

Stephen Douglas Barrett